RetinalGenix Technologies (RTGN) Change in Accured Expenses (2021 - 2026)

RetinalGenix Technologies has disclosed Change in Accured Expenses across 6 years of filings, most recently posting $104757.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $104757.0, up 8233.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $107340.0 (up 2494.63% YoY), and the FY2025 annual result was $3840.0, changed 0.0% from the prior year.
• Change in Accured Expenses came in at $104757.0 for Q1 2026 at RetinalGenix Technologies, up from -$111709.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $406560.0 in Q4 2023 to a low of -$156781.0 in Q2 2023.
• The 5-year median for Change in Accured Expenses is $1460.0 (2022), against an average of $31001.0.
• Across the five-year window, Change in Accured Expenses slumped 372.9% in 2022 and soared 15392.29% in 2024, its largest moves.
• RetinalGenix Technologies' Change in Accured Expenses stood at -$110265.0 in 2022, then surged by 468.71% to $406560.0 in 2023, then sank by 136.11% to -$146806.0 in 2024, then gained by 23.91% to -$111709.0 in 2025, then surged by 193.78% to $104757.0 in 2026.
• The last three Change in Accured Expenses figures came in at $104757.0 (Q1 2026), -$111709.0 (Q4 2025), and $20947.0 (Q3 2025), per Business Quant data.